Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer
European Journal of Cancer Care, 09/10/09
Heras P et al. – Patients with breast carcinoma often develop bone metastases that carry a high risk of complications. In general, ibandronate was well tolerated with very rare grade 3 or 4 toxicity. In this study, ibandronate was shown to be significantly more effective than placebo as a treatment for metastatic bone disease from breast cancer using multiple end points.
Related Articles
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study
Journal of Bone and Mineral Metabolism, 11/09/09
Relevance Score: 88%
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/23/09
Relevance Score: 87%
Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw
Journal of Clinical Oncology, 10/12/09
Relevance Score: 77%
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Osteoporosis International, 10/06/09
Relevance Score: 77%
Today in Bone/Cartilage...keeping you current
Receive free subspecialty "5-minute updates" via email
mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients prognosis
Medical Oncology, 12/04/09
Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo
Investigational New Drugs, 12/04/09
Interventional radiology procedures in the treatment of bone metastasis
Bulletin du Cancer, 12/01/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Bevacizumab and breast cancer: current therapeutic progress and future perspectives
Expert Review of Anticancer Therapy, 12/04/09
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
Cancer Treatment Reviews, 12/04/09
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
Cancer Treatment Reviews, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


